IBRANCE (palbociclib) is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with:
Clinical effectiveness of IBRANCE in combination with an aromatase inhibitor is based on the benefit observed in patients treated with IBRANCE in combination with letrozole for the treatment of postmenopausal women with advanced breast cancer.
Geriatrics (≥ 65 years of age):Of 444 patients who received IBRANCE in PALOMA-2, 181 (41%) patients were ≥65 years of age. Of 347 patients who received IBRANCE plus fulvestrant, 86 patients (25%) were ≥65 years of age. No overall differences in the safety and efficacy of IBRANCE were observed between these patients and younger patients in either study. Anemia was reported more frequently in patients ≥65 than in patients <65 years of age treated with IBRANCE plus letrozole, whereas similar incidences were reported in both age groups for patients treated with IBRANCE plus fulvestrant.
Pediatrics (< 18 years of age): Based on the limited data submitted and reviewed by Health Canada, the safety and efficacy of IBRANCE in pediatric patients have not been established; Therefore, Health Canada has not authorized an indication for pediatric use (See WARNINGS AND PRECAUTIONS, Special Populations; and ACTION AND CLINICAL PHARMACOLOGY, Special Populations).
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at